Tamoxifen Citrate
Formulation and Evaluation of Tamoxifen Citrate Loaded Transdermal Reservoir Gel Drug Delivery Systems
... Background: Successful treatment of cancer is yet remained as a challenging concern in public health. Transdermal delivery of hormonal therapy offers several advantages over the oral route associated with potential side ...
11
Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy
... compound, is the first choice for hormonal treatment of breast cancer in both post and premenopausal women for the last few decades. It is often used as an adjuvant therapy following primary treatment of early stage ...
12
ENHANCEMENT OF THE SOLUBILITY AND THE DISSOLUTION RATE OF TAMOXIFEN CITRATE SOLID DISPERSION USING SOLUPLUS BY SOLVENT EVAPORATION TECHNIQUE
... On oral administration, only a limited amount of TMX is absorbed and reaches the blood circulation due to the low water solubility and an extensive first-pass metabolism [4,5]. Accordingly, there are numerous approaches ...
6
Biochemical and immunohistochemical investigations on bone formation and remodelling in ovariectomised rats with tamoxifen citrate administration
... after tamoxifen citrate administration was studied via biochemical and immuno- histochemical ...+ tamoxifen. Following ovariectomy, tamoxifen citrate (10 mg/kg) was given ...
9
Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and <em>in-vitro</em> evaluation
... Nanoparticles (3 mg) containing tamoxifen citrate were taken in 1 mL phosphate buffer, pH 7.4, in 2 mL Eppendorf tube and kept in an incubator shaker at 37 ° C. Numbers of such tubes were kept for analysis ...
10
PHYSICOCHEMICAL CHARACTERIZATION OF – CYCLODEXTRIN COMPLEXES OF TAMOXIFEN CITRATE AND PHASE SOLUBILITY STUDIES
... drug Tamoxifen citrate form an inclusion complex with -cyclodextrin in the ratio ...1:1. Tamoxifen citrate entered into the hydrophobic cavity of -CD which makes the solubility of ...
8
Biodegradable Guar Gum Nanoparticles as Carrier for Tamoxifen Citrate in Treatment of Breast Cancer
... On comparison of the results of biodistribution from both the formulation of drug in the present study it is observed that, till 12 hrs after administration the maximum uptake and retent[r] ...
10
Nutritional, therapeutic, and pharmaceutical potential of plant gums: A review
... polysaccharides are used in drug delivery mainly for treatment of treatment of breast cancer.. Tamoxifen citrate (TMX) (a.[r] ...
19
Les traitements médicaux de l’oligoasthénozoospermie idiopathique
... Pure human follicle-stimulating hormone has a role in the treatment of severe male infertility by assisted repro- duction: Norfolk's total experience.. Tamoxifen citrate ther[r] ...
10
POLYCYSTIC OVARY SYNDROME TREATMENT POSSIBILITIES: FROM CONVENTIONAL THERAPIES TO EMBARKING ON NOVEL STRATEGIES OF CURE
... letrozole, Tamoxifen citrate, a Selective Estrogen Receptor Modulator(SERM), remains a reliable choice of treatment for PCOS more so, in clomiphene citrate resistant patients, with an optimum dose of ...
13
Bone loss and the aromatase inhibitors
... Letrozole Letrozole is superior to megestrol acetate in the treatment of advanced breast cancer and is clearly superior to tamoxifen as first-line therapy in high-risk or advanced disease (Buzdar et al, 2001; ...
7
Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer
... with tamoxifen is also effective in the metastatic setting and, although not curative, extends ...survival. Tamoxifen is the recommended treatment modality for premenopausal breast cancer patients and for ...
15
Acquisition of epithelial mesenchymal transition phenotype in the tamoxifen resistant breast cancer cell: a new role for G protein coupled estrogen receptor in mediating tamoxifen resistance through cancer associated fibroblast derived fibronectin and β1 integrin signaling pathway in tumor cells
... The EGFR/ERK signaling pathway is directly responsible for increased β 1-integrin expression in MCF-7R cells EGFR is involved in the induction of tamoxifen resist- ance and is known to activate the MAPK/ERK and ...
18
Click here to download PDF version of the article !
... with tamoxifen in a randomized European Organization for Research and Treatment of Cancer (EORTC) phase II/III trial ...the tamoxifen group ...with tamoxifen, are awaited ...
7
Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process
... in tamoxifen-resistant breast cancer is significantly improved, and our results also suggests that H19 is associated with TAM resistance in breast ...ameliorate tamoxifen resistance and promote cell ...
12
Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women
... incorporated into the adjuvant treatment of breast cancer. We have studied the changes in reproductive hormones, pituitary responses to hypothalamic-releasing hormones, and endometrial histology during treatment with the ...
8
Tamoxifen activity against Plasmodium in vitro and in mice
... clear tamoxifen levels during a week after ...of tamoxifen adminis- tered orally reaches the circulation, and blood tamoxifen concentration decreases by ~ 90% at 7 days post admin- istration in mice ...
7
Electrochemical Oxidation of Tamoxifen Revisited
... disease, tamoxifen still remains the endocrine treatment of choice and has been used successfully by millions of women ...[3]. Tamoxifen may also act as a chemopreventive agent in healthy ‘at risk’ women, ...
14
A mechanism for tamoxifen-induced cancer
... breast. Tamoxifen, toremifene and raloxifen are SERMs and they were used for treatment of breast ...cancer. Tamoxifen and toremifene but not raloxifen have been approved for breast cancer ...treatment. ...
5
Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
... 3125), tamoxifen (n = 3116) or a combination of anastrozole and tamoxifen (n = ...3125; tamoxifen, n = 3116: total 6241) and the hormone receptor positive subpopulation (84% of ITT: anastrozole, n = ...
10